A Timeline for the Initiation of the RV144 Prime-Boost Trial By Richard Jefferys 1995-2001: U.S. Military HIV Research Program/Thai Ministry of Public Health collaboration tests various combinations of ALVAC prime/Env protein boost vaccines, eventually choosing to move ahead with the…
PHS Panel Embraces Treatment Interruption "[Single episode treatment interruption] may be offered to patients with immune reconstitution, although participation in a controlled trial would be preferred. ... The long-term safety and efficacy of this approach are not known." Source: Guidelines…
Tangle of Interests and Disclosure Omissions Cracks Authors' Case for Early, Aggressive Treatment By Mike Barr "Treatment Perfected" Parallel realities, of sorts, presented themselves last month to medical literature news junkies -- which includes a goodly share of the TAG…
Brown University Clinician Leads the Way in Providing Competent Care to Coinfected Injectors By Tracy Swan Directly Observed Peg-IFN? A majority of the estimated 4 million hepatitis C virus (HCV) infections in the United States result from injection drug use…
Mike Barr and Rob Camp -- The article on the HIV Web sites and how their sponsors might influence their reporting is groundbreaking. TAG could do a great Sunday New York Times Magazine piece using these tables as the essential…
Does Gilead's Famed 903 Study Really Show You What They Tell You It Shows? By Steven Miles, M.D. Betting on Holy Water "Tenofovir/FTC Is Superior to Combivir!!" Is this really believable? Or how about "AZT/3TC equals ABC/3TC"?? Of course not…
By Mike Barr Even the researchers admit any definitive conclusions must await more rigorous investigation. But on the eve of World AIDS Day the news of a possible novel, less onerous, and much more affordable approach to the treatment of…
Why the Tap 'n' Drainers Have Always Been Wrong; Plus, a New Theory About MDR HIV By Richard Jefferys The Primacy of Immune Activation Project Inform, the country's longest serving community-based AIDS treatment information organization, has been sponsoring scientific think…
Vaccine Scientists Struggle to Come to Grips With the Field's "Berlin" By Richard Jefferys Technologically Challenged? The AIDS Vaccines 2004 Conference was held from August 30-September 1 in Lausanne, Switzerland, the first of these meetings to be held outside the…
Gilead 2-in-1 Opens Door to Impending One-Pill Triple Combo By Rob Camp GSK's, a Sort of Snoozer In early August the FDA announced the approvals of two fixed-dose combination (FDC) antiretroviral drug products. FDCs are combinations of two previously approved…